TELA Bio Inc.
TELA evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $56.4M
- Lead Asset:
- ovitex (Approved)
What it means
What to watch
Prepared research question
What matters most for TELA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TELA
TELA Bio Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, primarily through its OviTex product line for hernia repair and plastic surgery.
Key risk: Negative net income
BioSniper Score
Based on 4 of 6 signals
Market Cap
$56.4M
Cash Runway
—
Lead Asset
ovitex (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for TELA Bio Inc..
TELA Bio Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, primarily through its OviTex product line for hernia repair and plastic surgery.
- Cash & equivalents of $30.4M as of 2026-06-30 [sec].
- Total revenue of $19.3M and net income of -$11.3M as of 2026-06-30 [sec].
- Shareholders' equity of -$15.9M as of 2026-06-30 [sec].
- OviTex products have received 510(k) clearances from the FDA [sec_mda · as of 2026-03-25].
- Announced $17M annual expense reduction and cash runway extension into 2028 [news · published 2026-08-31].
What works
- Strongest quarter on record in Q1 2025 with revenue of $80.3 million for full year 2025, up 16% from 2024 [sec · filed 2026-04-30].
- Closed on a $70.0 million credit facility from Perceptive Advisors, providing additional financial flexibility [sec · filed 2026-04-30].
- OviTex PRS portfolio supported by non-human primate data showing more rapid tissue integration compared to market-leading biologic matrix [sec_mda · as of 2026-05-13].
What to weigh
- Net income of -$11.3M as of 2026-06-30 indicates ongoing losses [sec].
- Shareholders' equity of -$15.9M as of 2026-06-30 suggests negative net worth [sec].
- Revenue dip of 4% in Q2 2026, though international growth and improved gross margins were noted [news · published 2026-08-11].
- Cash runway extension into 2028 required a 20% workforce reduction and $17M annual expense cuts, indicating financial strain [news · published 2026-08-31].
From the filings
Quoted directly from source documents.
OviTex products have 510(k) clearance
“Our OviTex products have received 510(k) clearances from the U.S. Food and Drug Administration”
SEC MD&A · March 25, 2026
Risks & what to watch (4)›
Key risks
- Negative net income — Net income of -$11.3M as of 2026-06-30 indicates ongoing losses [sec].
- Negative shareholders' equity — Shareholders' equity of -$15.9M as of 2026-06-30 suggests negative net worth [sec].
- Revenue decline in Q2 2026 — 4% revenue dip in Q2 2026 despite international growth [news · published 2026-08-11].
- Workforce reduction — 20% workforce streamlining and $17M annual expense cuts needed to extend cash runway [news · published 2026-08-31].
What to watch
- Execution of cost-reduction plan and its impact on cash runway into 2028 [news · published 2026-08-31].
- Commercial performance of larger OviTex PRS sizes launched in March 2025 [sec · filed 2026-04-30].
- International growth trajectory and its contribution to revenue [news · published 2026-08-11].
- Ability to achieve profitability given negative net income and equity [sec].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run TELA Bio Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TELA Bio Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$11M
Lead: Approved
2 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 2.5%
- Days to cover
- 4.1
- Shares short
- 765,765
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TELA short interestGovernance
Frequently asked questions
What is the AI investment thesis for TELA Bio Inc.?
TELA Bio Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, primarily through its OviTex product line for hernia repair and plastic surgery.
What is TELA Bio Inc.'s lead drug candidate?
TELA Bio Inc.'s most advanced tracked candidate is ovitex (Approved) for Hernia repair and abdominal wall reconstruction.
Who is the CEO of TELA Bio Inc.?
Ms. Heather C. Getz C.P.A., M.B.A. is the chief executive officer of TELA Bio Inc. (TELA).
Where is TELA Bio Inc. headquartered?
TELA Bio Inc. (TELA) is headquartered in Malvern, PA, United States.
What therapeutic areas does TELA Bio Inc. focus on?
TELA Bio Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.